A real-world study evaluating the efficacy and safety of kolopavivir capsules in combination with sofosbuvir tablets for chronic HCV treatment

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400091967

Enrollment

Unknown

Registered

2024-11-06

Start date

2023-12-11

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis C (CHC)

Interventions

Case group:NA

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Ages between 18 to 80 years, both genders are eligible; 2. All patients meet the diagnostic criteria of the "Guidelines for the Prevention and Treatment of Hepatitis C (2019 Edition)"; 3. HCV-infected individuals receiving the treatment regimen of hydrochloride kolopavir capsules/sofosbuvir tablets; 4. Patients who provide and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. HCV-infected individuals concurrently receiving other Direct-Acting Antivirals (DAAs). 2. Subjects with poor compliance who are unable to complete the treatment or follow-up.

Design outcomes

Primary

Measure	Time frame
liver function tests;HCVRNA;Kidney function;Complete blood count;	—

Countries

China

Contacts

Public ContactLi Jianping

Department of Hepatology,Guangzhou Eighth people's Hospital,Guangzhou Medical University, Guangzhou, China.

13570303667@126.com+86 135 7030 3667

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026